Idorsia
The purpose of Idorsia is to discover, develop and commercialize innovative medicines to help more patients.
Business Model:
Revenue: $50.7M
Employees: 1,001-5,000
Rankings
Industries / Tags:
Detailed Idorsia Information
Geographic Data
Address: Hegenheimermattweg 91
City: Allschwil
State: basel-country
Zip: 4123
Country: CH
Financial Info
Stage:
Raised Last:
$583M
Raised Total:$1B
Social
Facebook
Twitter
Linkedin
Crunchbase
Metrics
1,645,491Website Global Rank
17,256Website Monthly Traffic
Twitter Followers
Description
The purpose of Idorsia is to discover, develop and commercialize innovative medicines to help more patients. We have more ideas, we see more opportunities and we want to transform the horizon of therapeutic options. In order to achieve this, we will develop Idorsia into a leading biopharmaceutical company, with a strong scientific core. Headquartered in Switzerland – a biotech-hub of Europe – Idorsia is a high-potential biopharmaceutical company, specialized in the discovery, development and commercialization of innovative small molecules, with the aim of transforming the horizon of therapeutic options.
Contact Phone:
Contact Email:
Idorsia went public on 6/16/2017 on the SIX
Listed Exchange:
SIX
IPO Date:
6/16/2017
Ticker Symbol:
IDIA
Live
Opened: -/share
| EBITDA | - |
| Total Cash | - |
| Total Debt | - |
| Total Revenue | - |
| Total Profit (Gross) | - |
| PE Ratio | - |
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 1/2023 | Santhera Pharmaceuticals | Post-IPO Equity | 5.4M |
| 9/2021 | Santhera Pharmaceuticals | Post-IPO Equity | 0 |
| 9/2021 | Santhera Pharmaceuticals | Post-IPO Equity | 0 |
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
